PRKDC and osteosarcoma: Our findings confirm the significance and efficacy of targeting METTL3‐mediated m6A modification and DNA‐PKcs in overcoming drug resistance in osteosarcoma, potentially offering a novel therapeutic strategy for this challenging malignancy.